NEW YORK (Reuters Health) – In patients with rheumatoid arthritis (RA) in remission taking conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), cutting the drug dose in half could lead to more disease flares, according to a randomized controlled trial. Sustained remission…